Am Regent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AM REGENT
AM REGENT has eighty-two approved drugs.
There are eleven US patents protecting AM REGENT drugs.
Summary for Am Regent
| US Patents: | 11 |
| Tradenames: | 75 |
| Ingredients: | 72 |
| NDAs: | 82 |
Drugs and US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | AP | RX | Yes | Yes | 11,364,260 | ⤷ Start Trial | ⤷ Start Trial | |||
| Am Regent | TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE | trimethobenzamide hydrochloride | INJECTABLE;INJECTION | 091329-001 | Mar 8, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | METHOCARBAMOL | methocarbamol | SOLUTION;IM-IV | 207496-001 | Jun 22, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | 11,975,022 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-002 | Oct 8, 2020 | 11,590,097 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | 9,376,505 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | 11,123,321 | ⤷ Start Trial |
| Am Regent | DEXFERRUM | iron dextran | INJECTABLE;INJECTION | 040024-001 | Feb 23, 1996 | 5,624,668 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Am Regent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0318840 | ⤷ Start Trial |
| South Korea | 20080082674 | ⤷ Start Trial |
| Poland | 1973549 | ⤷ Start Trial |
| Lithuania | 1973549 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Am Regent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 300689 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 1853250 | PA2014022 | Lithuania | ⤷ Start Trial | PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 0694547 | C300071 | Netherlands | ⤷ Start Trial | PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920 |
| 2957286 | CR 2018 00043 | Denmark | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
